PI3K inhibitor BKM120 + rituximab
Phase 1CompletedDevelopment Stage
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
Jul 21, 2014 → Apr 9, 2019
About PI3K inhibitor BKM120 + rituximab
PI3K inhibitor BKM120 + rituximab is a phase 1 stage product being developed by Novartis for Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue. The current trial status is completed. This product is registered under clinical trial identifier NCT02049541. Target conditions include Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02049541 | Phase 1 | Completed |
Competing Products
8 competing products in Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Avastin + Gemcitabine + Oxaliplatin + Pegaspargase + Dexamethasone | Eli Lilly | Phase 2 | 52 |
| High dose of methotrexate + Gemcitabine + Pegaspargase + Dexamethasone | Eli Lilly | Phase 2 | 52 |
| Camrelizumab | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| SHR-1210 | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| avelumab | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| carfilzomib | Amgen | Phase 1 | 32 |
| IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody) | Innovent Biologics | Phase 1/2 | 40 |